Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
Completed
- Conditions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1961
- Registration Number
- NCT05984615
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT05977322
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸BAMF Health, Grand Rapids, Michigan, United States
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1125
- Registration Number
- NCT05976230
- Locations
- 🇯🇵
Novartis Investigative Site, Yamaguchi, Japan
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 348
- Registration Number
- NCT05976243
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Little Rock Allergy and Asthma Clnc, Little Rock, Arkansas, United States
🇺🇸Kern Research, Bakersfield, California, United States
Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Completed
- Conditions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124018
- Registration Number
- NCT05974397
- Locations
- 🇨🇳
Novartis, Taipei, Taiwan
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204691
- Registration Number
- NCT05974345
- Locations
- 🇫🇷
Novartis Investigative Site, Rueil-Malmaison, France
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France
Completed
- Conditions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT05964946
- Locations
- 🇫🇷
Novartis, Paris, France
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
Completed
- Conditions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9870
- Registration Number
- NCT05963282
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT05959304
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Completed
- Conditions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT05950308
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath